Until the day she dies, Sandy Morris is hunting for a comma and a clause.
In May 2018, the 53-year-old mother of three learned she has ALS, a diagnosis made even more devastating by a somber directive to get her affairs in order period. The finality speaks to the absence of an effective treatment, yet alone a cure, for the neurodegenerative disease also known as Lou Gehrig's disease.
Since the diagnosis, Morris has sought to give future ALS patients some measure of optimism, amending the 'get your affairs in order' instruction to add 'but, there's something worth looking into.' While medical advances in areas like gene therapy show potential to change the course of other potentially fatal diseases, a disease-modifying treatment in ALS has proved elusive.
"In cancer, you have a shot," Morris said in an interview. "Not always a great shot, but you have one. In this land, everybody is just like, 'We don't have anything.'"
But now, Morris said she has reason for hope, stemming from a first-of-its-kind study in ALS that will test five experimental drugs simultaneously in a platform trial. Five drugmakers selected for the trial were announced last week.
After years of work, the broader promise of these adaptive trials, which allow more flexibility to make changes throughout, is beginning to be put into action. This trial aims to accelerate the pace of ALS research and may prove to be a template for other rare diseases as well, experts said.
The design offers advantages for each key stakeholder in drug development: patients have a lower probability of receiving placebo due to the study's shared control arm; companies get quicker topline results at lower cost; and researchers talk of the study as an "endpoint engine" that could advance their scientific understanding of the disease.
Formidable challenges remain in the way of broader adoption, particularly among leaders of the drug industry. The ALS study uses experimental treatments from small biotechs instead of industry giants, which can afford to prioritize control and pay for their own studies instead.
Even so, it's an exciting advancement in ALS research. Morris, who is also a leader of the patient group I Am ALS, said the trial can bring hope to future patients, even if it comes too late to help her.
"It's not going to save me. I'm not in time for any of this," Morris said. "But, dammit, we have to make it better for the rest."
Merit Cudkowicz understands speed. After 25 years specializing in ALS research, Cudkowicz is fully aware of how ALS changes a patient's life, shortening their life expectancy from decades to just years. The disease has a roughly three-year median survival.
Merit Cudkowicz
Massachusetts General Hospital
That life-changing diagnosis came in May 2018 for Sean Healey, then the CEO of an asset management firm worth more than $8 billion. After resigning from that post, Healey connected with Cudkowicz as he searched for treatment options and realized there was an opportunity to accelerate the pace of research.
Just six months from his diagnosis, Healey raised $40 million to launch a research center at Massachusetts General Hospital. Now, slightly less than a year after being established, the Sean M. Healey & AMG Center for ALS Research is aiming to start the platform trial in the first few months of 2020.
And earlier this month, the Healey Center announced the first five therapies to be tested in the study, including drugs from Biohaven Pharmaceutical and Ra Pharmaceuticals.
Cudkowicz, who leads the study, as well as the Healey Center and Mass General's neurology department, said in an interview the trial aims to have 160 patients for each of five treatments. The primary outcome will be whether or not the drug boosted a functional rating score for ALS after six months. One placebo group will be shared for all treatment arms, and more drugs can be added as the study continues. (Cudkowicz cautioned the plan is nearing finalization with the Food and Drug Administration, so specifics could still change.)
Moving quickly is the trial's aim. Cudkowicz called the study "an endpoint engine" that can help create better outcome measurements, including future surrogate markets, pushing ALS research forward. She estimated topline results to come 12 to 18 months after the study begins, depending on enrollment speed.
But those goals are steps toward the actual mission: developing a cure, Healey wrote in an email to BioPharma Dive.
"Of course, we all understand that the most meaningful measure of success will be the development of effective treatments and ultimately a cure," Healey wrote. "I am convinced that the Platform Trial, along with other initiatives we are supporting, will substantially accelerate the achievement of this ultimate goal."
For the first five biotechs, the decision to participate was a no-brainer. The center and other groups are footing the majority of the cost, leaving the companies' primary expense to simply provide their drug.
Out of about 30 applicants, the Healey Center selected five drugs for the study, most notably Biohaven's verdiperstat and Ra Pharma's zilucoplan. The trial also will test therapies from Implicit Bioscience, Prilenia Therapeutics and Clene Nanomedicine.
Cudkowicz said the typical applicants were small biotechs that "have great ideas but not deep pockets."
The expense of clinical trials limits the ability for biotechs to run multiple studies simultaneously across a range of indications. Instead, companies typically focus on a lead indication, with others following in succession.
"As a small company, we live and die by being able to run efficiently and test our hypotheses," said Irfan Qureshi, Biohaven's vice president of neurology.
For instance, Biohaven's verdiperstat is in Phase 3 testing for multiple system atrophy, and Ra Pharma's zilucoplan is focused on a different neuromuscular disorder called generalized myasthenia gravis.
"We wanted to do the study anyway, but to be honest, we probably wouldn't have gotten to it for years if this had not come along," Ra Pharma CEO Doug Treco said in an interview.
While smaller biotechs have bought into the platform trial and its efficiencies, missing from the list of initial participants are industry leaders. With a market value of about $2 billion, Biohaven is the largest company involved.
Cudkowicz noted larger drugmakers have shown interest in roundtable discussions that shaped the trial's design, and there's always potential to add additional therapies after the trial starts.
"We're talking to the other ones like Biogen and Sanofi," she said. "They are interested and came to these meetings, but they have the money to do it on their own."
But the main hang-up for these companies is ceding control, said Scott Berry, a senior statistical scientist and co-founder of Berry Consultants, which worked on the ALS platform trial.
"All these companies have people that this is what they do for a living they run trials, and they know how to do it," Berry said. "To hand your drug to somebody else and you don't have control over making sure that happens is uncomfortable for companies, and it's different than what they usually do."
Additionally, with lengthy protocols and many moving parts, the trials are complex and typically require extensive consulting to get off the ground. Running a multi-arm study also brings statistical pitfalls that can make it harder to interpret results.
Beyond ALS, adaptive trials have been started in breast cancer, Alzheimer's disease and glioblastoma. Experts say they anticipate other rare diseases as logical future targets for these studies.
"As these start to get developed and people see them, in most rare diseases there will be people jumping on board," predicted Berry.
Biohaven's Qureshi added that once companies are willing to experiment beyond typical drug development, these trials could be particularly attractive for rare diseases by easing enrollment concerns where there are "not patients growing on trees," he said.
But the ultimate test to get the industry's full attention, Qureshi said, would be such a study yielding an approved drug.
In the meantime, platform trials appear here to stay. Janet Woodcock, the long-time leader of the FDA's drug review center, has been an influential supporter for these study designs. Just this month, the agency finalized guidance on ALS research that advised companies to consider adaptive trial designs.
Earlier this year, Woodcock told BioPharma Dive she believes these types of studies will gain ground as patients become more vocal about how trials are conducted.
Morris said the platform trial has struck her with its compassion. While no patient wants to be put on placebo, it's of particular importance in a disease that progresses as rapidly and severely as ALS, leaving most patients the time to try one study in their life.
She already took her shot, enrolling in a clinical trial that required a three-month observation period before receiving treatment, which then carried a 50% chance of being placebo. "We are humans," she said. "We aren't zebrafish."
Now, she wants to take the baton from "the voices in the graveyard" and pass it onto the next generation. Platform trials may allow her to cover a bit more ground before that hand-off, eventually reaching a day when people might be able to live with ALS, like HIV.
"ALS's day is coming," Morris said.
Read more from the original source:
First-of-its-kind trial in ALS spurs hope for brutal disease - BioPharma Dive
- Is there an alternative to radiation - November 8th, 2009 [November 8th, 2009]
- Taiwan exploring how nanotech affects health - November 8th, 2009 [November 8th, 2009]
- A new way of treating cancer on the way? - November 8th, 2009 [November 8th, 2009]
- Lasers can destroy cancer cells - November 8th, 2009 [November 8th, 2009]
- Fluorescent molecules can be biomarkers - November 8th, 2009 [November 8th, 2009]
- Quick blood tests by using a nanodevice - November 8th, 2009 [November 8th, 2009]
- Where will medicine be 20 years from now - November 8th, 2009 [November 8th, 2009]
- History of nanotechnology - November 8th, 2009 [November 8th, 2009]
- Nanotech and Cancer - November 8th, 2009 [November 8th, 2009]
- Nanotechnology in medicine - November 8th, 2009 [November 8th, 2009]
- How does cancer start - January 25th, 2010 [January 25th, 2010]
- Lung cancer symptoms - January 26th, 2010 [January 26th, 2010]
- Signs of breast cancer - January 27th, 2010 [January 27th, 2010]
- Famous people with cancer - January 29th, 2010 [January 29th, 2010]
- Metastatic renal cancer - January 30th, 2010 [January 30th, 2010]
- What causes skin cancer - January 31st, 2010 [January 31st, 2010]
- How many people die from cancer each year - February 1st, 2010 [February 1st, 2010]
- How much money is spent on cancer research - February 2nd, 2010 [February 2nd, 2010]
- Colon cancer warning signs - February 4th, 2010 [February 4th, 2010]
- Prostate cancer symptoms - February 4th, 2010 [February 4th, 2010]
- Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy - April 25th, 2012 [April 25th, 2012]
- Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy, other neurologic disorders - April 25th, 2012 [April 25th, 2012]
- Nanomaterial properties in complement activation: lessons from nanomedicine - Video - May 4th, 2012 [May 4th, 2012]
- OMICS Group :: International Conference and Exhibition on Nanotechnology - May 4th, 2012 [May 4th, 2012]
- Use of Nanotechnology in Medicine [FOX 11-27-2011] - Video - May 4th, 2012 [May 4th, 2012]
- Cancer Nanomedicine - Detection - Video - May 4th, 2012 [May 4th, 2012]
- Cancer Nanomedicine - Video - May 4th, 2012 [May 4th, 2012]
- HBIO Reports First Quarter 2012 Revenue Growth of 8% Over First Quarter 2011 - May 5th, 2012 [May 5th, 2012]
- Nano science, focus of Education Ministry - May 7th, 2012 [May 7th, 2012]
- Drug-resistant Bacteria - Designing Nanoparticles For High Antibiotic Doses - May 7th, 2012 [May 7th, 2012]
- Research and Markets: Global Market for Nano Silver - May 10th, 2012 [May 10th, 2012]
- Cracking study makes nanotech breakthrough - May 10th, 2012 [May 10th, 2012]
- Nanoparticles may pose environmental threat - May 16th, 2012 [May 16th, 2012]
- Global Nanobiotechnology Industry - May 17th, 2012 [May 17th, 2012]
- 'Inability to give back Singur land my biggest regret' - May 20th, 2012 [May 20th, 2012]
- 'KOREA PACK 2012' for Packing process industry to be held at KINTEX - May 23rd, 2012 [May 23rd, 2012]
- New ISO Technical Report Guides Characterization of Nanomaterials in Toxicology - May 29th, 2012 [May 29th, 2012]
- DNA strands create tiniest Smileys - May 30th, 2012 [May 30th, 2012]
- Health and fitness agenda: Evolution Asia Yoga Conference - June 2nd, 2012 [June 2nd, 2012]
- UC Davis work in humanities receives $150,000 in UC-wide grants - June 2nd, 2012 [June 2nd, 2012]
- Computer-designed proteins 'may help fight variety of flu viruses' - June 3rd, 2012 [June 3rd, 2012]
- 'Nano technology' [program can pay off big for IRSC students - June 3rd, 2012 [June 3rd, 2012]
- Computer-designed proteins programmed to disarm variety of flu viruses - June 3rd, 2012 [June 3rd, 2012]
- Jugaad innovators don't plan - they improvise - June 6th, 2012 [June 6th, 2012]
- Health and fitness agenda: World Blood Donor Day - June 9th, 2012 [June 9th, 2012]
- OMICS Group :: Journal of Nanomedicine - June 9th, 2012 [June 9th, 2012]
- Researchers develop a 'time bomb' to fight cardiovascular disease - June 10th, 2012 [June 10th, 2012]
- Nanotechnologists develop a 'time bomb' to fight cardiovascular disease - June 10th, 2012 [June 10th, 2012]
- 'Time bomb' to fight cardiovascular disease developed - June 11th, 2012 [June 11th, 2012]
- Asia's First Graphene Nano-Tech Facility Opens In Singapore - June 13th, 2012 [June 13th, 2012]
- How worms are pioneering remote control medicine - June 13th, 2012 [June 13th, 2012]
- Golden Helix Establishes Direct Presence in Japan - June 13th, 2012 [June 13th, 2012]
- STDs Blocked by Nano Gel, Study Suggests - June 15th, 2012 [June 15th, 2012]
- Real Products, Different Results - June 15th, 2012 [June 15th, 2012]
- The Puridone Program - A Breakthrough for Painkiller Addiction - June 15th, 2012 [June 15th, 2012]
- Six startup medical device firms compete in Memphis for fame and fortune - June 19th, 2012 [June 19th, 2012]
- International Nanomedicine Conference bound for Sydney: July 2-4, 2012 - June 19th, 2012 [June 19th, 2012]
- Taming light with graphene - June 21st, 2012 [June 21st, 2012]
- Today on New Scientist: 25 June 2012 - June 26th, 2012 [June 26th, 2012]
- A step towards the future - July 1st, 2012 [July 1st, 2012]
- Genia Technologies Collaborates with Professors Jingyue Ju at Columbia and George Church at Harvard to Develop a ... - October 4th, 2012 [October 4th, 2012]
- Scientists Invited To Submit Proposals For Biological Research In Space - October 4th, 2012 [October 4th, 2012]
- Research and Markets: Micro-Nano Technology XIII from the 13th Annual Conference of Chinese Society of Micro-Nano ... - October 6th, 2012 [October 6th, 2012]
- $80M research facility to open at UMass Lowell - October 6th, 2012 [October 6th, 2012]
- Nano-revolution in drugs delivery - October 8th, 2012 [October 8th, 2012]
- SENAI/SESI of Sao Paulo Selects NanoProfessor as Foundation for "Nanomundo" Nanotechnology Education Initiative - October 8th, 2012 [October 8th, 2012]
- Delivering an integral approach to emotional and mental health - October 9th, 2012 [October 9th, 2012]
- NanoGuardian's On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting - October 11th, 2012 [October 11th, 2012]
- Il Nano Mondo del professor Ennio Tasciotti - Video - October 30th, 2012 [October 30th, 2012]
- Deakin University - Practical Science - Nano medicine - Video - October 30th, 2012 [October 30th, 2012]
- 2012 Deakin University 3 Minute Thesis Finalist - Jarrad Altimari - Video - October 30th, 2012 [October 30th, 2012]
- Nano Medicine from "Development of Nanotechnology in Hong Kong" - Video - October 30th, 2012 [October 30th, 2012]
- NANO Medicine 1 3 xvid - Video - October 30th, 2012 [October 30th, 2012]
- Nanolääke // Nano medicine - Video - October 30th, 2012 [October 30th, 2012]
- NANO Medicine (1-3) - Video - October 30th, 2012 [October 30th, 2012]
- Jefferson County, Colorado's Bioscience Industry - Video - October 30th, 2012 [October 30th, 2012]
- NanoMission - Nanomedicine NanoBot - Video - October 30th, 2012 [October 30th, 2012]
- Study aims to unlock mysteries of autism - November 20th, 2012 [November 20th, 2012]
- Catherine Griwkowsky - November 22nd, 2012 [November 22nd, 2012]
- Kulkarni to be feted at Bangalore Nano 2012 - November 26th, 2012 [November 26th, 2012]